Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

126.86 +1.41 (+1.12%)
Streaming Delayed Price Updated: 9:36 AM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 751,953
Open 125.83
Bid (Size) 126.79 (100)
Ask (Size) 126.94 (100)
Prev. Close 125.45
Today's Range 125.83 - 127.57
52wk Range 76.66 - 125.96
Shares Outstanding 2,531,374,696
Dividend Yield 2.68%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stay informed with the top movers within the dow jones index on Thursday. ↗
Via Chartmill
What's going on in today's session: dow jones movers ↗
Via Chartmill

Performance

YTD
+19.2%
+19.2%
1 Month
+6.0%
+6.0%
3 Month
+6.7%
+6.7%
6 Month
+18.8%
+18.8%
1 Year
+59.2%
+59.2%

More News

Read More
News headline image
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Wednesday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
Via Investor Brand Network
The Quest to Repair What Multiple Sclerosis Takes Away
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Via Investor Brand Network
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
From BioMedWire
Via GlobeNewswire
News headline image
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
From BioMedWire
Via GlobeNewswire
News headline image
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
From Merck & Co., Inc.
Via Business Wire
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill
Exploring the top movers within the dow jones index during today's session. ↗
Via Chartmill
Which dow jones stocks are moving on Monday? ↗
Via Chartmill
Top dow jones movers in Monday's session ↗
Via Chartmill
News headline image
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
From Merck & Co., Inc.
Via Business Wire
Stay informed with the top movers within the dow jones index on Thursday. ↗
Via Chartmill
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill
News headline image
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
From Merck & Co., Inc.
Via Business Wire
Explore the top gainers and losers within the dow jones index in today's session. ↗
Via Chartmill
News headline image
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
From Merck & Co., Inc.
Via Business Wire
News headline image
3 Dividend Stocks to Hold for the Long Haul ↗
Via The Motley Fool
Topics Intellectual Property
Discover which dow jones stocks are making waves on Monday. ↗
Via Chartmill
News headline image
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
From Merck & Co., Inc.
Via Business Wire
Stay informed with the top movers within the dow jones index on Friday. ↗
Via Chartmill

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 126.86
When was Merck & Co last traded?
The last trade of Merck & Co was at 06/26/26 09:36 AM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 321.13B
How many shares of Merck & Co are outstanding?
Merck & Co has 321B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.